Recordati Overview

  • Founded
  • 1926

Founded
  • Status
  • Public

  • Employees
  • 4,300

Employees
  • Stock Symbol
  • REC

Stock Symbol
  • Investments
  • 21

  • Share Price
  • $43.90

  • (As of Friday Closing)

Recordati General Information

Description

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company's revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Contact Information

Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
MIL
Primary Office
  • Via Matteo Civitali, 1
  • 20148 Milan
  • Italy
+39 02 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recordati Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$43.90 $44.03 $33.51 - $56.15 $9B 205M 208K $1.74

Recordati Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 9,134,386 14,008,795 12,480,515 9,142,629
Revenue 1,949,048 1,868,119 1,651,582 1,658,847
EBITDA 607,794 683,787 646,138 601,557
Net Income 358,165 456,327 404,651 412,879
Total Assets 3,909,785 3,188,559 3,335,245 3,146,485
Total Debt 1,671,232 1,123,379 1,305,067 1,232,809
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recordati Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recordati‘s full profile, request access.

Request a free trial

Recordati Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promot
Pharmaceuticals
Milan, Italy
4,300 As of 2023
0.000 0000-00-00
000000000000

00000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Mumbai, India
00000 As of 0000
00000000

000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
0000 000000000
Daix, France
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recordati Competitors (55)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cipla Corporation Mumbai, India 00000 00000000
000000000 000000 Corporation Daix, France 000 00000 00000000 00000
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
00000 000000000000 Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
00000000 000000 Corporation Tokyo, Japan 00000 00000000
You’re viewing 5 of 55 competitors. Get the full list »

Recordati Patents

Recordati Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200397728-A1 Pharmaceutical formulation for carglumic acid Inactive 30-May-2019 0000000000
US-20220071938-A1 Treatment of hyperammonemia in patients with renal insufficiency Inactive 22-May-2019 0000000000
US-20220040129-A1 Treatment of hyperammonemia in patients with renal insufficiency Inactive 22-May-2019 0000000000
EP-3972580-A1 Treatment of hyperammonemia in patients with renal insufficiency Pending 22-May-2019 0000000000
US-20200368192-A1 Treatment of hyperammonemia in patients with renal insufficiency Inactive 22-May-2019 A61K31/197
To view Recordati’s complete patent history, request access »

Recordati Executive Team (10)

Name Title Board Seat Contact Info
Robert Koremans MD Chief Executive Officer & Board Member
Luigi La Corte Chief Financial Officer
Fritz Squindo Board Member & General Manager
Federica De Medici Director Investor Relations & Corporate Communications
Gabriele Finzi Executive Vice President Corporate Development and Licensing
You’re viewing 5 of 10 executive team members. Get the full list »

Recordati Board Members (10)

Name Representing Role Since
0000000 000000000 Self Board Member 000 0000
000000 000000000 Recordati Board Member 000 0000
00000 0000000 Recordati Board Member & General Manager 000 0000
00000 00000 Self Board Member & Vice Chairman 000 0000
000 00000000 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Recordati Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recordati Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recordati‘s full profile, request access.

Request a free trial

Recordati Investments & Acquisitions (21)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000 16-Mar-2022 0000000000 00000 Pharmaceuticals 00000000
00000000 (000 23-Oct-2019 000000000 00000 Buildings and Property 0000000 0
000000000 31-Dec-2018 0000000000 000.00 Pharmaceuticals 000000 00
0000000 00000 11-Jun-2018 0000000000 000.00 Food Products 0000000 0
Three Bayer Consumer Health Brands (Ransipeg, TransipegLib and Colopeg) 18-Dec-2017 Corporate Asset Purchase 000.00 Buildings and Property 000000 00
You’re viewing 5 of 21 investments and acquisitions. Get the full list »

Recordati Subsidiaries (6)

Company Name Industry Location Founded
EUSA Pharma Pharmaceuticals Hemel Hempstead, United Kingdom 2006
0000000 00000 Food Products Milan, Italy 0000
000000000 Pharmaceuticals Boulogne, France 0000
000000 000000 Pharmaceuticals Puteaux, France 0000
00000 00000 000000 Pharmaceuticals Madrid, Spain 0000
You’re viewing 5 of 6 subsidiaries. Get the full list »

Recordati ESG

Risk Overview

Risk Rating

Updated September, 30, 2022

28.23 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 473

Rank

0.00

Percentile

To view Recordati’s complete esg history, request access »

Recordati Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000000000 01-Jan-1986 000000000000000000 Completed
  • 000000000
To view Recordati’s complete exits history, request access »